相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Steven D. Nathan
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes
Steven D. Nathan et al.
CHEST (2023)
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
Aaron Waxman et al.
EUROPEAN RESPIRATORY JOURNAL (2023)
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Marc Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2023)
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
Steven D. Nathan et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Syndrome of Combined Pulmonary Fibrosis and Emphysema An Official ATS/ERS/JRS/ALAT Research Statement
Vincent Cottin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension
Sylvia M. Nikkho et al.
PULMONARY CIRCULATION (2022)
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen
Christopher S. King et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2021)
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Aaron Waxman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
Steven D. Nathan et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
Steven D. Nathan et al.
LANCET RESPIRATORY MEDICINE (2021)
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis
Steven D. Nathan et al.
CHEST (2020)
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
Steven D. Nathan et al.
LANCET RESPIRATORY MEDICINE (2019)
Pulmonary hypertension in chronic lung disease and hypoxia
Steven D. Nathan et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis
Vincent Cottin et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Martin Kolb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia
Tamera J. Corte et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan A Parallel, Randomized Trial
Ganesh Raghu et al.
ANNALS OF INTERNAL MEDICINE (2013)
Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water
Vincent Cottin
EUROPEAN RESPIRATORY JOURNAL (2013)
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Pulmonary Hypertension as a Prognostic Indicator at the Initial Evaluation in Idiopathic Pulmonary Fibrosis
Motohiro Kimura et al.
RESPIRATION (2013)
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
V. Cottin et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis
Robert M. Jackson et al.
LUNG (2010)
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
David A. Zisman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prostaglandin E2 induces fibroblast apoptosis by modulating multiple survival pathways
Steven K. Huang et al.
FASEB JOURNAL (2009)
Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Steven D. Nathan et al.
RESPIRATION (2008)
Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis
Steven D. Nathan et al.
RESPIRATORY MEDICINE (2008)
Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis
David A. Zisman et al.
RESPIRATORY MEDICINE (2007)
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
A. F. Shorr et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
CJ Lettieri et al.
CHEST (2006)
Prostaglandin E-2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation
JE Kolodsick et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2003)